Saltar ao contenido
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avanzado
  • Lenalidomide selectively inhib...
  • Citar
  • Text this
  • Enviar este rexistro por email
  • Imprimir
  • Exportar rexistro
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Permanent link
Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Detalles Bibliográficos
Main Authors: Jadersten, M, Pellagatti, A, Forsblom, A, Emanuelsson, E, Merup, M, Samuelsson, J, Wainscoat, J, Boultwood, J, Hellstorm-Lindberg, E
Formato: Conference item
Publicado: 2005
  • Existencias
  • Descripción
  • Títulos similares
  • Staff View

Títulos similares

  • Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
    por: Pellagatti, A, et al.
    Publicado: (2006)
  • Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
    por: Pellagatti, A, et al.
    Publicado: (2007)
  • Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
    por: Jädersten, M, et al.
    Publicado: (2009)
  • Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
    por: Scharenberg, C, et al.
    Publicado: (2011)
  • Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
    por: Martin Jädersten, et al.
    Publicado: (2009-12-01)

Opciones de procura

  • Historial de Procuras
  • Procura avanzada

Buscar Máis

  • Revisar o catálogo
  • Lista alfabética
  • Explore Channels
  • Reservas de curso
  • Novos exemplares

Necesita Axuda?

  • Consello de procura
  • Consulte a un Bibliotecario
  • Preguntas Frecuentes